PropertyValue
is ?:annotates of
?:authorAffiliation
  • [\'Phase 1 Clinical Research Center, Huashan Hospital, Fudan University, Shanghai, China.\', \'Medical Science, Shanghai Junshi Biosciences Co., Ltd., Beijing, China.\', \'Department of Infectious Diseases, Huashan Hospital, Fudan University, Shanghai, China.\', \'CAS Key Laboratory of Microbial Physiological and Metabolic Engineering, Institute of Microbiology, Chinese Academy of Sciences, Beijing, China.\', \'Institute of Antibiotics, Huashan Hospital, Fudan University, Shanghai, China.\']
?:citedBy
  • -1
?:creator
?:doi
  • 10.1128/AAC.00350-21
?:doi
?:hasPublicationType
?:journal
  • Antimicrobial agents and chemotherapy
is ?:pmid of
?:pmid
?:pmid
  • 33972256
?:publication_isRelatedTo_Disease
?:rankingScore_SJR
  • 2.291
?:rankingScore_hIndex
  • 226
is ?:relation_isRelatedTo_publication of
?:title
  • Tolerability, Safety, Pharmacokinetics, and Immunogenicity of a Novel SARS-CoV-2 Neutralizing Antibody, Etesevimab, in Chinese Healthy Adults: a Randomized, Double-Blind, Placebo-Controlled, First-in-Human Phase 1 Study.
?:type
?:year
  • 2021

Metadata

Anon_0  
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://purl.org/net/provenance/ns#DataItem>
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://www.w3.org/2004/03/trix/rdfg-1/Graph>
<http://xmlns.com/foaf/0.1/primaryTopic> <https://research.tib.eu/covid-19/entity/33972256>
<http://xmlns.com/foaf/0.1/topic> Anon_0
<http://www.ontologydesignpatterns.org/cp/owl/informationrealization.owl#realizes> <https://research.tib.eu/covid-19/data/entity/33972256>
<http://purl.org/net/provenance/ns#createdBy>
Anon_1   (more)
expand all